MHRAapproval72% confidence
Clinical trials for medicines: modifying a clinical trial approval
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Eli Lilly.
Regulatory Analysis
Guidance on the various types of modifications that can be made to a clinical trial approval.
Supporting Context
- Therapeutic area
- Hematology · Myelofibrosis
- Sub-indication
- General
Related signal: Lilly presents promising Phase 1 data for first-in-class type II JAK2 inhibitor in myelofibrosis
Source
FDA document
View source